MDCX

Business Context and Reporting Period

Company: Medicus Pharma Ltd. (MDCX)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Medicus is a clinical-stage biotechnology company focused on developing SkinJect™, a dissolvable microneedle array delivering doxorubicin for the treatment of basal cell carcinoma (BCC). The company completed a reverse takeover in September 2023 and its initial public offering (IPO) in November 2024. It is classified as an emerging growth company and a smaller reporting company.

Key Financial Metrics

Note: The company has no revenue as it is in the clinical development stage. Margins are not applicable due to zero revenue.

Material Changes vs. Prior Period

• Expense Growth: Total operating expenses increased by 136% to $11.2 million, driven primarily by a 1,722% increase in R&D expenses ($3.5 million) due to the initiation of the Phase 2 clinical trial (SKNJCT-003) and a 69% increase in G&A expenses ($7.7 million) related to public company compliance, legal, and professional fees.
• Financing Activity: The company raised significant capital in 2024, including $5.2 million from convertible notes, $5.5 million from a private placement, and approximately $1.8 million net proceeds from its November 2024 IPO.
• Cash Position: Cash and cash equivalents more than doubled to $4.2 million, supported by financing activities which provided $12.7 million in cash inflows.
• Corporate Structure: Completed a 1-for-2 reverse stock split in October 2024 to meet Nasdaq listing requirements.

Guidance, Outlook, and Risks

Clinical Progress and Outlook

• Phase 2 Trial (SKNJCT-003): The company is actively recruiting for a randomized, double-blinded, placebo-controlled Phase 2 study for nodular BCC. As of March 2025, over 50% of the 60 expected patients have been randomized.
• Interim Data: A positively trending interim analysis announced in March 2025 indicated a complete clinical clearance rate of over 60% with no dose-limiting toxicities or serious adverse events.
• Capital Strategy: The company entered a Standby Equity Purchase Agreement (SEPA) in February 2025 for up to $15 million and completed a Regulation A offering in March 2025 raising $4.2 million to fund clinical trials.

Risks and Contingencies

• Going Concern: The auditor has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows. Continued operations depend on securing additional financing.
• Internal Controls: Management identified material weaknesses in internal controls over financial reporting as of December 31, 2024, specifically regarding the precision of transaction reviews and IT system policies.
• Regulatory Risk: Success depends on FDA approval of the product, which is not guaranteed. The company relies on a license from the University of Pittsburgh, which can be terminated if milestones are not met.

Investor Verification Checklist

• Cash Runway: Verify the burn rate against the $4.2 million cash balance and the $15 million SEPA facility to determine the timeline for the next capital raise.
• Phase 2 Enrollment: Confirm the pace of patient enrollment in the SKNJCT-003 trial and the timeline for final data readout.
• Internal Control Remediation: Review the company's plan and progress in remedying the identified material weaknesses in financial reporting controls.
• Licensing Milestones: Monitor compliance with the University of Pittsburgh license agreement milestones to avoid termination of IP rights.
• Regulatory Interactions: Track the status of the FDA meeting request planned for Q2 2025 following the interim analysis.